A detailed legal and policy analysis of IRS Code § 280E, its impact on cannabis and psilocybin industries, and the argument that psilocybin should not be treated as a Schedule I or II substance “within the meaning” of the Controlled Substances Act. This article explores tax challenges, legal interpretations, and scientific evidence supporting the rescheduling of psilocybin.
